1. Generics Bulletin
  2. >>Products

Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Approval Or Launch Will Trigger Notification To Market

 
• By Dean Rudge

Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.

Growth Strategy
Coherus is looking to drive revenue growth after a fall in 2022 • Source: Shutterstock

Coherus BioSciences will not disclose when or if it files its proposed biosimilar to Amgen’s Neulasta Onpro (pegfilgrastim) on-body injector device.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products